TIP30 overcomes gefitinib resistance by regulating cytoplasmic and nuclear EGFR signaling in non–small‐cell lung cancer

Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) (eg, gefitinib) exert potent therapeutic efficacy in non–small‐cell lung cancer (NSCLC) harboring EGFR‐activating mutations. However, the resistance to EGFR TKIs limits their clinical therapeutic efficacy. TIP30, a newly ident...

Descripción completa

Detalles Bibliográficos
Autores principales: Shuai, Shuai, Liao, Xueyang, Wang, Haixia, Liu, Lusha, Mei, Shiqi, Cao, Jiaxin, Wang, Senming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8486181/
https://www.ncbi.nlm.nih.gov/pubmed/34058054
http://dx.doi.org/10.1111/cas.15000

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8486181/
https://www.ncbi.nlm.nih.gov/pubmed/34058054
http://dx.doi.org/10.1111/cas.15000

Ejemplares similares